API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Blue Water expands its commercial portfolio by purchasing six FDA-approved assets across multiple indications, including cardiology, otic infections, and pain management. The assets also include Conjupri (levamlodipine), a calcium channel blocker for the hypertension.
Lead Product(s): Levoamlodipine
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Conjupri
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Blue Water Vaccines
Deal Size: $8.5 million Upfront Cash: $8.5 million
Deal Type: Acquisition June 14, 2023